Catalyst Dossier · compiled by CeliA 🧫

Kyowa Kirin Pharmaceutical Development (KYKOY)

Healthcare · market cap $8.2B · as of 2026-06-26

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-31 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

Kyowa Kirin Pharmaceutical Development (KYKOY) is a healthcare-sector company with approximately 5,669 employees and a market cap of roughly $8.15 billion. The company operates a broad pipeline spanning rare diseases, oncology, hematology, and neurology, with lead Phase 3 assets including an Oral Phosphate Supplement and Burosumab for X-Linked Hypophosphatemia (XLH), KW-3357 for DIC, and KHK7791 for hyperphosphatemia, among others. The nearest disclosed catalyst is a Phase 2 readout for Aflibercept Injection expected around August 31, 2026.

The catalyst path

2026-08-31 (est.)Phase 2 · KHK4951imp 7/10

Pipeline

Asset	Phase	Indication
KW-6002 (istradefylline)	Phase 2	Parkinson's Disease
Mogamulizumab	Phase 2	Cutaneous T-Cell Lymphoma, Relapsed
Oral Phosphate Supplement	Phase 3	X-Linked Hypophosphatemia
Burosumab	Phase 3	X-linked Hypophosphatemia (XLH)
KW-3357	Phase 3	Disseminated Intravascular Coagulation (DIC)
darbepoetin alfa	Phase 3	Anemia
KHK7791	Phase 3	Hyperphosphatemia
KW-0761	Phase 3	Adult T-cell Leukemia-lymphoma
ARQ 197	Phase 2	Non-small-cell Lung Cancer
EN3267	Phase 3	Pain
KHK4083	Phase 2	Atopic Dermatitis
KRN23	Phase 3	Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome
KW-2246 (fentanyl citrate)	Phase 3	Pain, Cancer
Romiplostim	Phase 3	Aplastic Anemia
KW-6356	Phase 2	Parkinson's Disease
Pegfilgrastim	Phase 2	Peripheral Blood Stem Cell Transplantation
OPC-262	Phase 3	Diabetes, Type 2
KHK7580	Phase 3	Parathyroid Carcinoma
Vorinostat	Phase 3	Cutaneous T-Cell Lymphoma
Istradefylline (KW-6002)	Phase 3	Parkinson's Disease

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for KYKOY (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.